Du koblet deg nå opp til et område
som er tilrettelagt for helsepersonell


JA, jeg er helsepersonellNEI, jeg er ikke helsepersonell
Mundipharma
Følgende artikler kan du lese ved å trykke på artikkelen, eller du kan bestille dem ved å kontakte Mundipharma AS.

Artikler vedrørende Norspan

Borchgrevink P, 2010 - Editorial comment - Long-term low-dose transdermal buprenorphine therapy for chronic noncancer pain. Scandinavian Journal of Pain 1 (2010) 120–121
Breivik et al, 2010 - A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scandinavian Journal of Pain 1 (2010) 122–141
Karlsson et al, 2009 - Efficacy and Safety of Low-Dose Transdermal Buprenorphine patches (5, 10, and 20 pg/h) versus Prolonged-Release Tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallel-group noninferiority study
Schutter et al, 2008 - Norspan PMS Germany - Chronic OA pain: efficacy and safety of a 7-day patch with low-dose buprenorphine
James et al, 2010 - A randomized, double-blind, double dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (Norspan/ BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain
Skurtveit et al, 2008 - Introduction of low dose transdermal buprenorphine - Did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
Gordon et al, 2010 - Buprenorphine transdermal system on adults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-level extension phase
Böhme et al, 2010 - Seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac. Results from a non-interventional study
Steiner D et al, 2011 - Efficacy and safety of Buprenorphine Transdermal System (BTDS) for chronic moderate to severe Low Back Pain: A Randomized, double-blind study
Nordbø A. et al, 201 - Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs

Artikler vedrørende buprenorfin

Vadivelu et al, 2008 - Management of chronic pain in the elderly: focus on transdermal buprenorphine
Kress HG, 2008 - Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine
Kusnik et al, 2008 - Transdermal buprenorphine in chronic pain: indications and clinical experience
Pergolizzi et al, 2010 - Review article Current knowledge of buprenorphine and its unique pharmacological profile
Guetti C. et al, 2011 - Transdermal buprenorphine for central neuropathic pain: Clinical reports
Van den Eynden B, 2008 - Transdermal Buprenorphine in The Management of Cancer Pain
Gianni W. et al. 2011 - Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old
Likar R, Transdermal buprenorphine in the management of persistent pain - safety aspects
Sittl R, 2005 - Transdermal buprenorphine in the treatment of chronic pain
Likar et al, 2008 - Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age
Koppert W et al, 2005 - Different profiles of buprenorphine-induced analgesia in a human pain model
Andersen T et al, 2011 – Effect of transdermal opioids in experimentally induced superficial, deep hyperalgesic pain
Budd K, 2003 - Buprenorphine and the transdermal system: The ideal match in pain management
Bachs et al, 1999 - Buprenorfin - en litteratur gjennomgang
 
Vennligst klikk her for å lese Legal Statement, og her for Personvern Policy som gjelder for disse sidene. Bruk av Mundipharma AS internettsider forutsetter at du aksepterer våre vilkår og betingelser. Disse internettsidene er kun beregnet for norske borgere.
Mundipharma AS     Tlf: 67 51 89 00     This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Mundipharma